INVO Fertility (IVF) investor relations material

Company overview and business model

• Operates as a healthcare services and technology company focused on expanding access to assisted reproductive technology (ART) through fertility clinics and proprietary devices.

• Principal strategy centers on acquiring, establishing, and operating profitable US-based fertility clinics, with four clinics currently in operation.

• Offers a range of fertility services, including IVF and intravaginal culture (IVC) enabled by the INVOcell® device, and continues to distribute INVOcell to third-party clinics.

• Recent acquisitions include Family Beginnings (Indiana) and full ownership of an Alabama clinic, expanding clinical footprint and service offerings.

Financial performance and metrics

• The acquisition of Wisconsin Fertility Institute in 2023 more than tripled annual revenue and added significant positive cash flow.

• Recent private placements and warrant exercises raised approximately $11.5 million in gross proceeds to support growth and liquidity.

• As of July 23, 2026, 2,295,035 shares of common stock were outstanding, with additional shares reserved for warrants, options, and incentive plans.

Use of proceeds and capital allocation

• Proceeds from the sale of shares to Alumni Capital LP may reach up to $15 million, potentially increasing to $50 million by mutual agreement.

• Funds are expected to be used for acquisitions of additional fertility clinics, capital expenditures, working capital, and general corporate purposes.

• Management retains broad discretion over the allocation of proceeds, which may be invested in short-term, interest-bearing securities pending use.